Last reviewed · How we verify

NCT06921551

Exploratory Pilot Study on the Prolonged Use of the ABLE Exoskeleton in Multiple Sclerosis

Active, enrolled NA Last updated 27 January 2026
What this trial tests

NA trial testing ABLE Exoskeleton in Multiple Sclerosis in 19 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
7 April 2025
Primary endpoint
7 May 2026
7 May 2026

Quick facts

Lead sponsorABLE Human Motion S.L.
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment19
Start date7 April 2025
Primary completion7 May 2026
Estimated completion7 May 2026
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

ABLE Human Motion S.L.

Who can join

Adults 18 to 70, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to explore the potential clinical benefits of the ABLE Exoskeleton as part of a rehabilitation program in people with multiple sclerosis. The main question it aims to answer is: Can a rehabiliation program with the ABLE Exoskeleton help to mantain the physical and psychosocial health of people with multiple sclerosis? Participants will: * Have a gait training session of 60 min with the exoskeleton once a week for 12 months at the clinic * Have an evaluation (tests and questionnaires) every 3 months at the clinic

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ABLE Exoskeleton

Trials testing the same drug.

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other ABLE Human Motion S.L. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06921551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing